News

Methylisothiazolone (MIT) and 5-chloro-methylisothiazolinone (CIT) are active ingredients of biocidal products. They are used – alone or in combination (Kathon™)  – as preservatives in many convenience goods (e.g. cosmetics). They are very often detectable in indoor air. They have inter alia irritating and sensitising properties. The Ad-hoc Working Group for Indoor Air Guide Values and the Human Biomonitoring Commission of the Federal Environment Agency (UBA) are currently evaluating these substances. FoBiG elaborates the scientific background on behalf of the UBA.

The European Commission started a public consultation on the criteria for identifying endocrine disruptors (ED) on 26th September 2014 (deadline: 16 January 2015). This is part of the impact assessment process in the context of the implementation of the plant protection product regulation and the biocidal products regulation. For further information see here. While the Commission is discussing the criteria for identifying ED and their possible regulatory consequences the criteria proposed by the Endocrine Disruptors Expert Advisory Group (JRC, 2013) were already applied to DEHP and other phthalates by the Danish Environmental Protection Agency  to propose an Annex XIV entry. Do you have any further questions on endocrine disruptors in the REACH context?

For companies seeking support for preparing Applications for Authorisation under REACH or wishing to exchange experiences ECHA provides a new partners service to find suitable partners for their authorisation applications. For more information click here. On the list of partners provided by ECHA you will also find FoBiG and RPA Ltd.:
For REACH authorisation FoBiG is working closely with the UK consultancy RPA Ltd. in Loddon. Both consultancies cooperate(d) successfully in several past and ongoing authorisation projects for chemical companies and consortia. Whereas RPA provides special expertise in socioeconomic analysis (SEA) and the technical and economic aspects of the evaluation of alternatives, FoBiG’s main tasks are improving the CSR (particularly the exposure assessment, to be able to conclude on low risks) and assessing the hazard and risk profiles of potential alternative substances.

FoBiG staff member Jan Oltmanns together with colleagues from Öko-Institut and EUROSTAT compared classification information from REACH registration dossiers with legally binding harmonised classifications for a set of 142 very high production substances. The analysis, just published in Regulatory Toxicology & Pharmacology, showed that a substantial number of substances had stricter classifications in the REACH registration dossiers and were often classified for additional endpoints not covered by the harmonised classification. The authors concluded that REACH leads to an improved hazard characterisation.

ECHA recently announced an update of CHESAR, now including so-called SCEDs (Specific Consumer Exposure Determinants), developed by industry associations. SCEDs describe specific conditions of use for consumer exposure scenarios. Recently, FoBiG, on behalf of the Federal Institute for Risk Assessment (BfR, Bundesinstitut für Risikobewertung), compared and evaluated parameters and defaults used in common Tier I consumer exposure tools (ECETOC TRA, REACT, EGRET) (report soon to be published by BfR, manuscript for peer review journal in preparation).